Clinical trials: Artery Disease, Peripheral
Peripheral Arterial Disease, Iliac Artery Stenosis
Drug-eluting PTA Balloon Dilatation Catheter in the Treatment of Peripheral Artery Stenosis or Occlusion
Clinical study on safety and efficacy of ZENFlow™ drug-eluting PTA balloon dilatation catheter in the treatment of iliac, femoral and popliteal artery stenosis or occlusion
- Conditions
- Peripheral Arterial Disease, Iliac Artery Stenosis, Femoral Artery Stenosis, Popliteal Artery Stenosis
- Trial name
- NCT03844724
- Testing
- ZENFlow™ Drug-eluting PTA Balloon Dilatation Catheter, Peripheral Balloon Dilatation Catheter
- Volunteers
- 204 people
- Sponsor
- Zhejiang Zylox Medical Device Co., Ltd.
Peripheral Artery Disease
Alprostadil Liposomes for Injection for Lower Extremity Arteriosclerosis Obliteran
This is a randomized, positive-control, multicenter, multiple-dose, dose-escalation phase II trial
- Trial name
- NCT04197323
- Testing
- Alprostadil liposomes for injection
- Where
- China
- Volunteers
- 20 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Intermittent Claudication, Peripheral Vascular Disease
Efficacy and Safety of NM-702 Tablets for the Treatment of Intermittent Claudication
NM-702 oral tablets are being developed for the treatment of Intermittent Claudication, a primary early stage indication of peripheral arterial disease (PAD).
- Trial name
- NCT00102050
- Testing
- NM-702 (phosphodiesterase inhibitor)
- Where
- 17 sites in United States
- Volunteers
- 390 people
- Sponsor
- Nissan Chemical Industries
Peripheral Artery Disease
Bard LifeStent and Lutonix DCB for Treatment of Long Lesions in Femoropopliteal Arteries
Objective of this study is to evaluate the safety and efficacy of Lutonix 035 Drug Coated Dilatation PTA Catheter with Bard LifeStent Vascular Stent (hereinafter referred to as LifeStent) for treatment of long (10-24 cm) lesions…
- Trial name
- NCT02278991
- Testing
- Lutonix Drug Coated Balloon
- Where
- 12 sites in Germany, Greece and 1 more
- Volunteers
- 149 people
- Sponsor
- C. R. Bard
Peripheral Arterial Disease
Stellarex Vascular E-Registry
Prospective, international, multi-center, single arm, observational study to continue to assess the treatment by the Stellarex™ OTW Drug-coated Angioplasty Balloon in superficial femoral and/or popliteal arteries according to the…
- Trial name
- SAVER (NCT02769273)
- Testing
- Percutaneous Transluminal Angioplasty
- Where
- 46 sites in Austria, Belgium and 4 more
- Volunteers
- 1,900 people
- Sponsor
- Spectranetics Corporation
Critical Limb Ischemia, Buerger Disease
Study to Assess the Efficacy and Safety of CLBS12 in Patients with Critical Limb Ischemia (CLI)
A prospective, open label, controlled, randomized, double arm, multi-center study to assess the efficacy and safety of CLBS12 in patients with critical limb ischemia (CLI) due to arteriosclerosis obliterans (ASO) with a single…
- Conditions
- Critical Limb Ischemia, Buerger Disease, Thromboangiitis Obliterans, Atherosclerosis Obliterans
- Trial name
- NCT02501018
- Testing
- CLBS12, SOC
- Where
- 12 sites in Japan
- Volunteers
- 33 people
- Sponsor
- Lisata Therapeutics, Inc.
Magnetic Resonance Angiography, Peripheral Vascular Diseases
Magnevist (SH L 451A) Intra-individual Dose Comparison Study in Magnetic Resonance Angiography
The objective of the study was to compare the efficacy of Magnevist (SH L 451 A) at doses of 0.1 mmol/kg and 0.2 mmol/kg in contrast-enhanced 3D-Magnetic Resonance Angiography in three regions (abdominal, femoral, and leg…
- Conditions
- Magnetic Resonance Angiography, Peripheral Vascular Diseases, Peripheral Arterial Diseases
- Trial name
- NCT00652418
- Testing
- Gadopentetate dimeglumine (Magnevist, BAY86-4882, SH L 451A)
- Where
- 3 sites in Japan
- Volunteers
- 12 people
- Sponsor
- Bayer
Atherosclerosis, Arteriosclerosis
BIOLUX P-I First in Man Study
A prospective, multi-centre, randomized controlled, First in Man study to assess the safety and performance of the coated Passeo-18 Lux Paclitaxel releasing PTA Balloon Catheter vs.
- Conditions
- Atherosclerosis, Arteriosclerosis, Vascular Disease, Peripheral Artery Disease
- Trial name
- NCT01221610
- Testing
- Passeo-18 Lux DRB, Standard PTA (POBA)
- Where
- 5 sites in Austria, Germany
- Volunteers
- 60 people
- Sponsor
- Biotronik AG
Peripheral Arterial Disease
The Jetstream G3™ Calcium Study
To investigate the treatment effects with the Jetstream G3 System in moderate to severely calcified peripheral artery disease in the common femoral, superficial femoral or popliteal arteries using intravascular ultrasound (IVUS).
- Trial name
- NCT01273623
- Testing
- Jetstream Atherectomy System
- Where
- 5 sites in United States
- Volunteers
- 55 people
- Sponsor
- Boston Scientific Corporation
Peripheral Arterial Disease (PAD)
Amplitude Vascular Systems (AVS) Lithotripsy POWER PAD 2 Trial
POWER PAD 2 is a prospective, single-arm, multicenter, non-randomized clinical study designed to demonstrate the safety and effectiveness of the Amplitude Vascular Systems (AVS) Pulse Intravascular Lithotripsy™ (Pulse IVL™)…
- Trial name
- POWER PAD 2 (NCT06457685)
- Testing
- Pulse Intravascular Lithotripsy (Pulse IVL)
- Where
- 19 sites in United States
- Volunteers
- 115 people
- Sponsor
- Amplitude Vascular Systems, Inc.
Peripheral Arterial Disease
DOTAREM®-Enhanced MRA Compared to GADOVIST®-Enhanced MRA in Patients With Abdominal or Lower Limb Arterial Diseases
This study is an intra-individual comparison of DOTAREM®-enhanced MRA and GADOVIST®-enhanced MRA in the diagnosis of clinically significant abdominal or lower limb arterial diseases.
- Trial name
- NCT00955617
- Testing
- Contrast-enhanced MRA - Imaging examination
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Guerbet
Intermittent Claudication, Peripheral Artery Disease
A Study of CK-2017357 in Patients With Peripheral Artery Disease and Symptomatic Claudication
The primary objective of this early-stage clinical study is to demonstrate an effect of single doses of CK-2017357 on measures of skeletal muscle function and fatigability in patients with peripheral artery disease and…
- Trial name
- NCT01131013
- Testing
- 375 mg CK-2017357, 500 mg CK-2017357
- Where
- 14 sites in United States
- Volunteers
- 61 people
- Sponsor
- Cytokinetics
Coronary Artery Disease, Peripheral Artery Disease
A Study to Collect Data on the Treatment Pattern of Xarelto + Acetylsalicylic Acid in the Routine Clinical Practice in Patients Who Are Suffering From a Condition That Narrows the Blood Vessels Supplying the Heart and / or a Condition That Most Commonly Narrows the Blood Vessel in the Legs
The study will focus on effectiveness and safety of rivaroxaban (Xarelto) when given together with acetylsalicylic acid (combination therapy) to patients suffering from coronary artery disease (a condition that affects the blood…
- Trial name
- XATOC (NCT04401761)
- Testing
- Rivaroxaban (BAY59-7939, Xarelto), Acetylsalicylic acid
- Where
- 10 sites in Belgium, China and 8 more
- Volunteers
- 3,189 people
- Sponsor
- Bayer
Peripheral Arterial Occlusive Disease
Study Comparing Synthetic Vascular Grafts in Patients With Peripheral Artery Disease (PAD) Who Require Artery Bypass.
To demonstrate the patency and safety of vascular grafts: EXXCEL and FUSION Bioline.
- Trial name
- FINEST (NCT01113892)
- Testing
- vascular grafts
- Where
- 25 sites in United States, Czechia and 1 more
- Volunteers
- 207 people
- Sponsor
- Maquet Cardiovascular
Coronary Artery Disease, Peripheral Arterial Disease
Evaluate Safety and Efficacy of Pronavi Microcatheter for Use in Endovascular Interventions
This is a prospective, multi-center, single-group post-market study. It is planned to be carried out in about 3 clinical institutions, and a total of 60 subjects are expected to be enrolled.
- Trial name
- NCT05747287
- Testing
- microcatheter
- Where
- 3 sites in China
- Volunteers
- 60 people
- Sponsor
- BrosMed Medical Co., Ltd
Intermittent Claudication
Efficacy and Safety of HMR1766 in Patients With Fontaine Stage II Peripheral Arterial Disease
The primary objective is to investigate in patients suffering from intermittent claudication due to Fontaine stage II Peripheral Arterial Disease (PAD) whether a 26-week treatment by HMR1766 on top of clopidogrel may result in an…
- Trial name
- ACCELA (NCT00443287)
- Testing
- ataciguat (HMR1766), cilostazol
- Where
- 7 sites in United States, Austria and 5 more
- Volunteers
- 553 people
- Sponsor
- Sanofi
Peripheral Arterial Disease
Post-Market Evaluation of Active Thrombectomy and Proximal Aspiration During Lower Extremity Tibial Interventions
Post-Market Evaluation of Active Thrombectomy and Proximal Aspiration during Lower Extremity Tibial Interventions
- Trial name
- Protexus 1 (NCT06929832)
- Volunteers
- 20 people
- Sponsor
- Protexa Endovascular, Inc.
Peripheral Vascular Diseases, Claudication
Safety and Effectiveness Study of EverFlex Stent to Treat Symptomatic Femoral-popliteal Atherosclerosis
This is a multi-center, non-randomized, single arm study to compare PTA and primary stenting using a single PROTÉGÉ® EverFlex™ stent to performance goals of PTA alone in the treatment of atherosclerotic superficial femoral artery…
- Trial name
- DURABILITY II (NCT00530712)
- Testing
- PROTÉGÉ® EverFlex™ Self-Expanding Stent System
- Volunteers
- 287 people
- Sponsor
- Medtronic Endovascular
Critical Limb Ischemia
Lutonix DCB Versus Standard Balloon Angioplasty for Treatment of Below-The-Knee (BTK) Arteries
To assess the safety and efficacy of the Lutonix Drug Coated Balloon (DCB) for treatment of stenosis or occlusion of native below-the-knee arteries.
- Trial name
- NCT01870401
- Testing
- Lutonix DCB, Uncoated PTA Catheter
- Where
- 51 sites in United States, Austria and 6 more
- Volunteers
- 442 people
- Sponsor
- C. R. Bard
Peripheral Arterial Disease, Peripheral Vascular Diseases
Real-World Registry Assessing the Clinical Use of the Lutonix 035 Drug Coated Balloon Catheter
The objective of this patient registry is to assess the clinical use of the Lutonix 035 DCB PTA Catheter in a heterogeneous patient population in a real world and on-label clinical application.
- Conditions
- Peripheral Arterial Disease, Peripheral Vascular Diseases, Arterial Occlusive Diseases
- Trial name
- SAFE-DCB (NCT02424383)
- Testing
- PTA (Lutonix® 035 DCB Catheter)
- Where
- 73 sites in United States
- Volunteers
- 1,005 people
- Sponsor
- C. R. Bard